| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P50 | author | Harvey White | Q1587897 |
| John Ioannidis | Q6251482 | ||
| Robert Califf | Q19281782 | ||
| Héctor Bueno | Q56435517 | ||
| Eric Boersma | Q57288054 | ||
| David J Moliterno | Q62070733 | ||
| Maarten L Simoons | Q63167072 | ||
| Pierre Theroux | Q114292241 | ||
| Ewout W. Steyerberg | Q37828851 | ||
| Cynthia M. Westerhout | Q39026574 | ||
| Paul W. Armstrong | Q39026591 | ||
| P2093 | author name string | Lars C Wallentin | |
| Adrián V Hernández | |||
| P2860 | cites work | Meta-analysis in clinical trials | Q27860779 |
| Antiplatelet therapy in non-ST-segment elevation acute coronary syndromes | Q28171226 | ||
| Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial | Q28185738 | ||
| Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes | Q28192208 | ||
| Elderly patients with acute coronary syndromes: higher risk and greater benefit from antiplatelet therapy and/or interventional therapies | Q28196885 | ||
| Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy | Q28213372 | ||
| Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE) | Q28213517 | ||
| Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators | Q48217387 | ||
| Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials | Q56944618 | ||
| The Early Glycoprotein IIb/IIIa Inhibition in Non–ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial: A randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients | Q57484335 | ||
| Age, risk-benefit trade-offs, and the projected effects of evidence-based therapies | Q57697531 | ||
| Age and outcome after acute coronary syndromes without persistent ST-segment elevation | Q73716497 | ||
| International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events i | Q74706424 | ||
| Early glycoprotein IIb/IIIa inhibitor use for non-ST-segment elevation acute coronary syndrome: patient selection and associated treatment patterns | Q81702355 | ||
| Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles | Q29618882 | ||
| Subgroup analysis and other (mis)uses of baseline data in clinical trials | Q30588628 | ||
| Comparison of evidence of treatment effects in randomized and nonrandomized studies | Q30699759 | ||
| Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease | Q33328574 | ||
| A Comparison of Aspirin plus Tirofiban with Aspirin plus Heparin for Unstable Angina | Q33502560 | ||
| Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. | Q33887755 | ||
| Platelet glycoprotein IIb/IIIa receptor antagonists and their use in elderly patients | Q33914229 | ||
| One thousand health-related quality-of-life estimates | Q33937445 | ||
| Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes | Q34042095 | ||
| Glycoprotein IIb/IIIa antagonists--from bench to practice | Q34607268 | ||
| Use of cardiovascular medications in the elderly | Q34809362 | ||
| Glycoprotein IIb-IIIa inhibitors in unstable coronary syndromes and percutaneous interventions--a conservative approach | Q35572163 | ||
| Optimizing glycoprotein IIb/IIIa receptor antagonist use for the non-ST–segment elevation acute coronary syndromes: risk stratification and therapeutic intervention | Q35575676 | ||
| Treating individuals 4: can meta-analysis help target interventions at individuals most likely to benefit? | Q36017145 | ||
| Platelet glycoprotein IIb/IIIa receptor antagonists in non-ST segment elevation acute coronary syndromes: a review and guide to patient selection | Q36019811 | ||
| Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT. | Q40829771 | ||
| Using numerical results from systematic reviews in clinical practice | Q41461392 | ||
| Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary Syndromes | Q44272454 | ||
| Inhibition of the Platelet Glycoprotein IIb/IIIa Receptor with Tirofiban in Unstable Angina and Non–Q-Wave Myocardial Infarction | Q44850788 | ||
| Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test | Q47423638 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | acute coronary syndrome | Q266018 |
| P304 | page(s) | 450-455 | |
| P577 | publication date | 2006-10-25 | |
| P1433 | published in | Heart | Q856338 |
| P1476 | title | Effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST segment elevation acute coronary syndromes: benefit and harm in different age subgroups | |
| P478 | volume | 93 |
| Q42539200 | Effects of glycoprotein IIb/IIIa blockers |
| Q37235603 | Platelet activation, and antiplatelet targets and agents: current and novel strategies. |
| Q43526375 | Quality-adjusted life-years as decisionmaker tools to address limitations inherent in number-needed-to-treat/harm values |
| Q39730277 | The Impact of Age on Effects of Pre-hospital Initiation of High Bolus Dose of Tirofiban Before Primary Angioplasty for ST-Elevation Myocardial Infarction |
| Q37835820 | Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. |
Search more.